17:34 , Mar 15, 2019 |  BC Week In Review  |  Clinical News

Shield's oral Feraccru non-inferior to IV Injectafer in Phase IIIb

Shield said oral Feraccru ferric maltol met the primary endpoint of non-inferiority to IV Injectafer ferric carboxymaltose in the Phase IIIb AEGIS-H2H trial to treat iron deficiency anemia in adults with inflammatory bowel disease (IBD)....
16:20 , Feb 9, 2018 |  BC Week In Review  |  Clinical News

Shield's Feraccru misses in Phase III for anemia

Shield Therapeutics plc (LSE:STX) reported that Feraccru ferric maltol missed the primary endpoint in the U.S. Phase III AEGIS-CKD trial to treat iron deficiency anemia (IDA) in patients with non-dialysis-dependent chronic kidney disease (CKD). On...
21:55 , Feb 5, 2018 |  BC Extra  |  Clinical News

Shield falls on Phase III Feraccru miss

Shield Therapeutics plc (LSE:STX) fell 65p (58%) to 47.50p on Monday after reporting that Feraccru ferric maltol missed the primary endpoint in the U.S. Phase III AEGIS-CKD trial to treat iron deficiency anemia (IDA) in...
20:59 , Dec 8, 2017 |  BC Week In Review  |  Clinical News

AMAG reports Phase III data for Feraheme in iron deficiency anemia

AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) reported data from a Phase III trial in 1,997 patients with iron deficiency anemia regardless of the cause who failed or could not tolerate oral iron therapy showing that 1.02 g...
19:36 , May 11, 2017 |  BC Week In Review  |  Clinical News

Daiichi starts Phase III HEART-FID trial of iron therapy for heart failure

American Regent Inc. began the Phase III HEART-FID trial of ferric carboxymaltose (Z-213) to treat heart failure with iron deficiency and reduced ejection fraction in about 3,014 patients. The double-blind, U.S. trial will evaluate incidence...
07:00 , Mar 28, 2016 |  BC Week In Review  |  Clinical News

Feraheme: Phase III started

AMAG began a double-blind, U.S. Phase III trial to compare 1.02 g IV Feraheme vs. 1.5 g IV Injectafer ferric carboxymaltose in about 2,000 patients. Feraheme is marketed in the U.S. to treat iron deficiency...
08:00 , Feb 23, 2015 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 2/20 cls Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) Cantor Fitzgerald Irina Rivkind Koffler Price target Buy 61% $33.68 William Blair Tim Lugo...
08:00 , Jan 12, 2015 |  BioCentury  |  Finance

Buyside view XXIII: Milestones galore

Stephen Hansen, Associate Editor and Jennifer Rhodes, Staff Writer   Buyside view XXIII The maturation of the biotech sector over the past few years finds fund managers focusing on a slew of clinical milestones and...
07:00 , Oct 27, 2014 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 10/24 cls Galenica Ltd. (SIX:GALN) UBS Guillaume van Renterghem Upgrade Neutral (from sell) 5% CHF797.5 Renterghem upgraded as Galenica stock...
07:00 , Sep 8, 2014 |  BC Week In Review  |  Clinical News

Ferinject ferric carboxymaltose: Phase IV data

The 52-week, double-blind, international Phase IV CONFIRM-HF trial in 304 stable ambulatory symptomatic patients with CHF and iron deficiency showed that IV Ferinject met the primary endpoint of improving 6MWT distance from baseline to week...